Quest Diagnostics stock gains 1.48 percent after Truist raises target

Published on 09/25/2026 at 11:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Quest Diagnostics stock traded at USD 236.44 on September 24, 2026, after Truist set a USD 260 target. Q2 revenue reached USD 3.04 billion, up 10.2 percent.

Automatisierter Laboranalysator mit Blutproben-Röhrchen in klinischem Diagnostiklabor — Quest Diagnostics US74834L1008 zeigt automatisierten Laboranalysator mit Blutproben in modernem Diagnostiklabor fotorealistisch dargestellt, Illustration mit AI erstellt.

Quest Diagnostics (ISIN US74834L1008) was trading at USD 236.44 on the NYSE on September 24, 2026, at 3:59 p.m. ET, up 1.48 percent from the previous close of USD 233.00. The move followed a fresh round of target increases, led by Truist Financial on September 21, 2026.

Truist lifts its target

According to MarketBeat, Truist raised its Quest Diagnostics price target to USD 260 from USD 250 on September 21, 2026, while maintaining a Hold rating. The USD 260 target lies 9.96 percent above the USD 236.44 reference price.

Baird also lifted its target to USD 260 from USD 255 and kept a Neutral rating, according to Yahoo Finance on September 22, 2026. The parallel target moves create a clear technical reference, but the stock remains USD 12.40 below the new USD 260 level.

Q2 growth meets a margin test

Quest Diagnostics generated USD 3.04 billion in Q2 2026 revenue, up 10.2 percent from Q2 2025, while reported EPS increased to USD 2.84 from USD 2.47. The figures come from the company's Q2 2026 earnings call published by Yahoo Finance on July 23, 2026.

Adjusted EPS reached USD 3.12, up from USD 2.62 in the prior-year quarter, a 19.1 percent increase. Reported operating income rose to USD 459 million from USD 438 million, but the reported operating margin declined to 15.1 percent from 15.9 percent.

Guidance sets the next hurdle

Management's 2026 outlook calls for revenue of USD 11.95 billion to USD 12.05 billion, reported EPS of USD 9.97 to USD 10.17 and adjusted EPS of USD 11.05 to USD 11.25, as detailed in the Yahoo Finance transcript. The outlook gives investors a concrete earnings benchmark after the second-quarter revenue advance, while the lower reported margin keeps cost execution in view.

Stock stays below its yearly high

Quest Diagnostics stock traded between USD 171.18 and USD 248.84 over the 52-week period shown in the quote, with a market capitalization of USD 26,096,592,120 and volume of 923,978 shares as of September 24, 2026. The reference price of USD 236.44 was 5.0 percent below the 52-week high.